| | NIH Awards $14.5 million Grant to the University of Maryland School of Medicine to Develop a Data Center for the Human Virome Program | |
The National Institutes of Health (NIH) has launched a new research program to understand how the viruses that live within the human body or on the skin—known as the human virome—can impact a person’s health.
As a critical part of NIH’s Human Virome Program, the Institute for Genome Sciences at the University of Maryland School of Medicine will receive $14.5 million over the next five years to establish a comprehensive and cutting-edge data center. The Consortium Organization and Data Collaboration Center (CODCC) will house and analyze data for the program. Owen White, PhD, Associate Director at IGS and Professor in the Department of Epidemiology and Public Health at UMSOM is leading effort to launch the CODCC.
Like the better understood microbiome...
| | $1M Grant from the Maryland Stem Cell Research Fund (MSCRF) Powers Novel Adipose Tissue Allograft Therapy for Osteoarthritis | GERMANTOWN, Md.--(BUSINESS WIRE)--Amarex today announced its partnership with Britecyte, the Maryland Stem Cell Research Fund (MSCRF) $1M clinical grant awardee, to support the development of Britecyte’s Adipose Tissue Allograft (BRC-OA) for the treatment of osteoarthritis (OA), a serious and debilitating disease with unmet needs. Britecyte is collaborating with Amarex and Regenerative Orthopedics & Sports Medicine (ROSM) to determine the safety and efficacy of the BRC-OA treatment, which has the potential to reverse the course of the OA disease.
MSCRF supports cutting-edge research and innovation in regenerative medicine in Maryland, helping.. | |  | TEDCO Announces Joint-Declaration Agreement Signing with Korea Venture Investment Corporation | |
COLUMBIA, Md., Nov. 6, 2025 /PRNewswire/ -- TEDCO, Maryland's economic engine for technology companies, announces a recent joint-declaration signing with South Korean entity, Korea Venture Investment Corporation (KVIC). KVIC's U.S. East Coast Office, located in New York City, supports Korean start-ups in gaining a global footprint and leading frontier technologies industries.
TEDCO is a driving force for economic development in Maryland. Through this agreement, the organization seeks to collaborate with KVIC to continue this growth, allowing for the development of both locales. Such cooperation may include joint workshops, acceleration programs and more. The formalization of these efforts represents a large step towards creating sustainable innovation ecosystems in both Maryland and South Korea by supporting the commercialization of startups' technologies and their international scaling.
| | | Applications Now Open for SPARK 2026 Pediatric Innovation Programs – Apply by November 17 | |
The SPARK for Innovations in Pediatrics Hub, sponsored by BARDA and powered by Children’s National Hospital, is now accepting applications for its 2026 programs supporting breakthrough pediatric medical countermeasures (MCMs). Innovators can apply for up to $200K in milestone-based non-dilutive funding through SPARK DEV or participate in the six-month, zero-cost SPARK Accelerator designed for academic teams and startups developing pediatric-focused technologies aligned with BARDA’s mission.
These programs provide access to expert mentorship, regulatory guidance, and technical support to help advance pediatric health innovations that protect our most vulnerable populations.
Learn more: https://www.mcm4kids.org
| | | BioBuzz Awarded TEDCO Equitech Growth Fund Grant to Launch MOORE-Bio Initiative | |
Baltimore, MD — [November 7, 2025] — BioBuzz has been awarded funding from TEDCO’s Equitech Growth Fund to launch MOORE-Bio (Mobilizing Opportunity & Outreach for Regional Excellence in Bio) — a statewide initiative designed to catalyze Maryland’s life sciences ecosystem by connecting inclusive talent supply with industry demand.
Through the MOORE-Bio initiative, BioBuzz will build a stronger, more connected infrastructure for Maryland’s bioeconomy — combining digital tools, community programming, and storytelling to create equitable access to jobs, career growth, and business opportunities across the state.
What the Program Will Deliver:
Maryland Life Sciences Hub & Two-Sided Talent Marketplace – A digital platform integrating media, events, and hiring to connect Maryland’s biotech...
| | | Save the Date: BioHealth Capital Region Week 2026 | |
The BioHealth Capital Region Week returns September 15–17, 2026, celebrating our region’s continued growth as a global hub for biotech, life sciences, and innovation. Mark your calendars for three days of thought leadership, networking, and collaboration as we convene government, academia, investors, and industry leaders to shape the future of health and technology.
The BioHealth Capital Region Forum will be held on the 15th and 16th, with the Crab Trap Competition on the 16th, and the Investment Conference on the 17th.
Those interested in committing as 2026 sponsors are encouraged to contact Rich Bendis at rbendis@biohealthinnovation.org or Andy Eckert at aeckert@biohealthinnovation.org for details on early opportunities and visibility.
| | | Altimmune Uses AI to Show Pemvidutide May Reduce Liver Scarring in Phase 2b Trial | |
GAITHERSBURG, Md., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced results from an artificial intelligence (AI)-based analysis of biopsies from the IMPACT Phase 2b trial of pemvidutide in patients with metabolic dysfunction-associated steatohepatitis (MASH).
The AI-based pathology tool Liver Explore™ showed that pemvidutide treatment resulted in significant reductions in the proportionate areas of early, advanced and total liver fibrosis compared to placebo at 24 weeks. These data are supported by significant improvements in non-invasive markers of fibrosis compared to placebo. The AI-based analysis will be presented on Saturday, November 8, in a late-breaking poster session at The Liver Meeting 2025, hosted by the American Association for the Study of Liver Diseases (AASLD) in Washington, D.C.
| | | BrainScope Names Matt Adams as Chief Executive Officer | |
ROCKVILLE, Md.--(BUSINESS WIRE)--BrainScope, a leading neurotechnology company that transforms brain health diagnostics through applying computational neuroscience to brain electrical activity, today announced the appointment of Matt Adams as its new Chief Executive Officer. Adams succeeds Laurie Silver, who will assume the role of President, continuing to help guide the company’s strategic direction and growth. Both Adams and Silver will serve on BrainScope’s Board of Directors.
Adams brings over two decades of experience leading MedTech companies through dynamic phases of innovation and scale with multiple successful exits. He has delivered more than $1.3 billion in realized shareholder value, combining...
| | | Celltrion Signs Licensing Deal with Maryland-Based Kaigene for Two Antibody Drug Candidates | |
Celltrion is joining hands one after another with domestic and global biotech companies to secure its next-generation antibody drug pipeline. Following a recent joint research agreement for multi-antibody immuno-oncology drug candidates, the company has also obtained exclusive development rights for antibody-based new drug candidates aimed at treating autoimmune diseases. According to the company, it plans to submit investigational new drug (IND) applications for a total of 13 drug candidates by 2028 and embark in earnest on new drug development.
On Nov. 4, Celltrion announced that it had signed an exclusive licensing agreement with Kaigene, a biotechnology company based in Maryland, United States, for two antibody-based new drug candidates for the treatment of autoimmune diseases. Under the deal, Celltrion will pay up to 1.06 trillion won (approximately $734.85 million), including an upfront payment of 11.4 billion won. Kaigene is a biotech...
| | | Veteran-Founded FireGate Biotech Launches to Advance Multi-Axis Immune Modulation | |
WASHINGTON, DC, UNITED STATES, November 4, 2025 /EINPresswire.com/ -- FireGate Biotech Inc., a veteran-founded translational immunology company, today formally announced its launch and development focus across a multi-axis immune-modulation platform built to restore dysfunctional immune environments in HIV, oncology, and inflammatory neuro-immune disorders.
FireGate’s approach integrates CCR5 signaling blockade, PD-L1 immune checkpoint modulation, and broadly neutralizing antibody (bNAb) platforms to support immune reset mechanisms in conditions marked by chronic inflammation, immune exhaustion, and viral or tumor persistence. The company’s development architecture emphasizes disciplined execution, mechanistic rigor, and transparent scientific governance aligned with modern federal translational research standards.
| | | CityBiz: Bora Pharmaceuticals Reinvests in Baltimore Facility | |
Bora Pharmaceuticals, a global leader in pharmaceutical manufacturing, is growing its presence in Baltimore.
The company made its entrance into Maryland last year when it acquired the 87,000 square-foot facility that formerly housed Emergent BioSolutions. Now, the Taiwan-based business is investing approximately $15 million to install a new automated line vial, syringe, and cartridge
According to the company, the facility provides drug product manufacturing services for sterile injectables and fill/finish services of vials and pre-filled syringes on four fill lines, freeze-drying, formulation development, and support services. This expansion introduces new technologies that require specialized expertise, creating pathways for future high-skilled jobs in advanced pharmaceutical manufacturing. The Baltimore site is Bora’s first sterile injectable manufacturing facility and 10th manufacturing and distribution site overall.
| | | | | |
